ReviewBritish journal of clinical pharmacology2013
Current and emerging antiviral treatments for hepatitis C infection.
Review in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Regulation of NS5B Polymerase Activity of Hepatitis C Virus by Target Specific Phytotherapeutics: An In-Silico Molecular Dynamics Approach.Cell biochemistry and biophysics · 2024Article
- Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC).International journal of epidemiology · 2024Article
- Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment.The Libyan journal of medicine · 2021Observational
- A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.Microbiology spectrum · 2021Article
- HCV infection status and care seeking among people living with HIV who use drugs in Vietnam.AIDS care · 2020Article
- The Elimination of Hepatitis C as a Public Health Threat.Cold Spring Harbor perspectives in medicine · 2020Review
- Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.Journal of the International AIDS Society · 2018Article
- Albumin nanostructures as advanced drug delivery systems.Expert opinion on drug delivery · 2016Review
- Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.Journal of viral hepatitis · 2015Article
- Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans.Journal of clinical and translational hepatology · 2015Article
- Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.Journal of the Royal Society, Interface · 2015Observational
- Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.Journal of virology · 2015Article
- Effect of zinc supplementation on viral response in patients with chronic hepatitis C and Beta thalassemia major, a pilot study.Journal of clinical and diagnostic research : JCDR · 2014Article
- The changing burden of hepatitis C virus infection in the United States: model-based predictions.Annals of internal medicine · 2014Article
- Eradication of hepatitis C infection: the importance of targeting people who inject drugs.Hepatology (Baltimore, Md.) · 2014Article
- Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0.Journal of clinical microbiology · 2013Article
- Experimental therapies for yellow fever.Antiviral research · 2013Review
- Hepatitis C transmission and treatment in contact networks of people who inject drugs.PloS one · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newly licensed direct acting antivirals for hepatitis C virus HCV are able to cure up to 75% of patients chronically infected with genotype-1 infection, which is the predominant HCV strain in Europe and North America. Emerging antiviral therapies promise further increases in virological response, as well as improved tolerability, reduced duration of therapy, and will potentially eliminate the need for interferon use. This review highlights the main therapeutic agents used in current standard of care, including telaprevir and boceprevir. It goes on to evaluate the mechanisms of emerging drugs, their stage of development and response rates seen in research to date. Finally, it projects into the not too distant future to consider treatment strategies involving combinations of agents and interferon-free therapies, and in which patients they might prove most successful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.